Gene Expression Biomarkers for Hepatitis B Treatment Response in PBMCs

47.25% of HBeAg-negative chronic hepatitis B patients achieved a virological response after 48 weeks of Peg-IFN-α treatment in this prospective study. The dataset likely contains mRNA expression levels for ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells, correlated with therapeutic outcomes. Hao Pang authored this 24.8 KB dataset, last updated in April 2026.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Assessing the diagnostic performance of gene expression biomarkers using ROC curve analysis.
• Identifying early indicators of HBsAg clearance based on dynamic changes in biomarker expression.
• Conducting multivariate analysis to find independent associations between biomarkers and treatment response.

Strengths

• Includes specific performance metrics, such as an AUC of 0.9230 for ADAR1 predicting virological response at week 24.
• Based on a prospective clinical study with a 48-week follow-up period.
• Results include response rates (47.25% VR, 35.16% SR) and multivariate analysis findings.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 24.8 KB file size suggests a very limited scope of data.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Data gathered from a prospective clinical study using real-time quantitative PCR on patient PBMCs.

Time Range

Study follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:12; freshness should be verified.

Geography

null